Erlotinib (Tarceva®):: Obtaining EU approval for treatment of metastasised pancreatic cancer

被引：0
|
作者：
不详
机构：
来源：
ONKOLOGIE | 2007年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：217 / 217
页数：1
相关论文
共 50 条
  • [1] Erlotinib contains approval expansion for treatment of metastasised pancreatic cancer
    Vollmer, Grit
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2007, 45 (04): : 340 - 340
  • [2] FDA drug approval summary:: Erlotinib (Tarceva®) tablets
    Cohen, MH
    Johnson, JR
    Chen, YF
    Sridhara, R
    Pazdur, R
    ONCOLOGIST, 2005, 10 (07): : 461 - 466
  • [3] Outcomes with erlotinib (Tarceva®) in a Yorkshire cancer centre
    O'Toole, L.
    Bond, M.
    Snee, M.
    LUNG CANCER, 2007, 57 : S7 - S7
  • [4] Targeting the epidermal growth factor receptor by erlotinib (Tarceva™) for the treatment of esophageal cancer
    Sutter, AP
    Höpfner, M
    Huether, A
    Maaser, K
    Scherübl, H
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (07) : 1814 - 1822
  • [5] Erlotinib in the treatment of advanced pancreatic cancer
    Kelley, Robin K.
    Ko, Andrew H.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 83 - 95
  • [6] Acneiform rash during lung cancer therapy with erlotinib (Tarceva®)
    Owczarczyk-Saczonek, Agnieszka
    Witmanowski, Henryk
    Placek, Waldemar
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2013, 30 (03): : 195 - 198
  • [7] The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer
    Perez-Soler, R
    CLINICAL CANCER RESEARCH, 2004, 10 (12) : 4238S - 4240S
  • [8] Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer
    Bao, Kunxi
    Li, Xiaobing
    He, Xiaojing
    Jian, Lingyan
    CLINICAL THERAPEUTICS, 2021, 43 (06) : 1107 - 1115
  • [9] Treatment of metastasised breast cancer
    不详
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2007, 67 (06) : 38 - 38
  • [10] Erlotinib (Tarceva) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2005, 47 (1205): : 25 - 26
12345